Pasar al contenido principal

FARMACOS METALICOS CON ESTRUCTURAS ALTERNATIVAS PARA EXPLORAR SU POTENCIAL EN QUIMICA BIOLOGICA E INDUCIR DAÑO MITOCONDRIAL Y ESPECIFICO EN CELULAS CANCERIGENAS

PID2019-106220RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dithiobiureas Palladium(II) complexes' studies: From their synthesis to their biological action

  • Herrero, Jorge M.
  • Fabra, David
  • Matesanz, Ana I.
  • Hernández, Carolina
  • Sánchez-Pérez, Isabel
  • Quiroga, Adoración G.
Dithiobiureas coordination chemistry towards palladium (II) ions and their possible application is presented and discussed. 1,6-(4-Methoxyphenyl)-2,5-dithiobiurea and 1,6-(4-chlorophenyl)-2,5-dithiobiurea afford two Pd(II) complexes with the general formula [Pd2(H2L)Cl2(PPh3)2]. The metal ion forms one chelate ring with the dithiobiurea, and binds to a triphenylphosphine and an additional leaving group cisplatin like. One of the complexes (1) is endowed not only with stability in DMSO and aqua solutions containing a biological buffer but also with cytotoxicity versus gastric cancer cell lines. Complex 1 does not interact covalently to DNA models, neither activates p53 or Checkpoint Kinase 1 key proteins for DNA damage response. Thus, we propose that complex 1 exerts its action by activating Mitogen-Activated Protein Kinases [p38, Extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs)] as cell death inductors., We acknowledge to Spanish MICINNgrant PID2019-106220RB100 and MetDrugs Network RED2018-102471T and COST Action CA18202 for research discussion. JMH was supported by a grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD programme)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulatory effects of miR-19a on MAD2 expression and tumorigenesis in gastric cancer

  • Bargiela-Iparraguirre, Jone
  • Herrero, Jorge M.
  • Pajuelo-Lozano, Natalia
  • Pérez, M.
  • Perona Abellón, Rosario
  • Quiroga, Adoración G.
  • Calés, Carmela
  • Sánchez-Pérez, Isabel
Gastric cancer (GC) is worldwide the sixth most diagnosed and third leading cause of cancer deaths, with poor and late prognosis, probably due to post-surgery adjuvant treatment resistance and lack of a thorough panel of prognostic markers. We have previously shown that mitotic arrest deficient 2 (MAD2, encoded by MAD2L1), a key protein of the spindle assembly checkpoint, is relevant in GC cells; its interference impairs migration and growth, while its overexpression correlates with tumorigenesis.1 Here we show a similar correlation with overall survival (OS) in a pilot patient series. We hypothesized that MAD2 overexpression might relate to micro-RNA (miRNA) deregulation. Bioinformatic analysis identified miRNAs specifically targeting MAD2L1-3′UTR. Expression of miR-19a and miR-203 inversely correlated with MAD2L1 expression in GC cell lines and patients' samples. A broader analysis using Cancer Genome Atlas data showed that only high miR-19 levels correlated with a better OS, especially in patients overexpressing MAD2L1. In GC cells, miR-19a expression reduced cell migration and invasion capability and increased apoptosis, in combination with classical and new antitumoral drugs. We propose that miR-19a is a critical regulator of MAD2 protein in GC, with potential clinical use as a prognostic biomarker, and as a model for MAD2 interfering agent design with therapeutical potential., MICINN grant number PID2019-106220RB100. Instituto de Salud Carlos III, Spain, grant PI20 0335, (all co-financed through Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa"). NPL was supported by a grant FPU15/04669, funded by Ministerio de Educación, Cultura y Deporte, Spain. JMH FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD programme)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells

  • Melones-Herrero, Jorge
  • Alcalá, Sonia
  • Ruiz-Cañas, Laura
  • Benitez-Buelga, Carlos
  • Batres-Ramos, Sandra
  • Calés, Carmela
  • Lorenzo, Óscar
  • Perona Abellón, Rosario
  • Quiroga, Adoración G.
  • Sainz, Bruno Jr.
  • Sánchez-Pérez, Isabel
Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority. Here, we studied the mechanism of action of the isomers trans and cis-[PtI2(isopropylamine)2] (I5 and I6, respectively) against gastrointestinal cancer cells. We demonstrate that I5 and I6 modulate mitochondrial metabolism, decreasing OXPHOS activity and negatively affecting ATP-linked oxygen consumption rate. Consequently, I5 and I6 generated Reactive Oxygen Species (ROS), provoking oxidative damage and eventually the induction of senescence. Thus, herein we propose a loop with three interconnected processes modulated by these iodido agents: (i) mitochondrial dysfunction and metabolic disruptions; (ii) ROS generation and oxidative damage; and (iii) cellular senescence. Functionally, I5 reduces cancer cell clonogenicity and tumor growth in a pancreatic xenograft model without systemic toxicity, highlighting a potential anticancer complex that warrants additional pre-clinical studies., This research was funded by PID2019-106220RB100, RTC2019-007227-1 granted by MICIU/ AEI / 10.13039/501100011033, and PID2022-137373OB-I00 granted by MICIU/ AEI / 10.13039/501100011033 / FEDER, UE. This study was supported by ISCIII FIS grants PI20/0335 (RP) and PI21/01110 (BSJ), co-financed through Fondo Europeo de Desarrollo Regional (FEDER) ’Una manera de hacer Europa’. JMH was supported by a grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD program). We thank Gonzalo Vílchez and Sofia Figueiras for their contribution to this work via Comunidad de Madrid grants PEJ-2020-AI/BMD-18538; PEJ-2021-TL/BMD-22441., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Trans-[Pt(amine)Cl2(PPh3)] Complexes Target Mitochondria and Endoplasmic Reticulum in Gastric Cancer Cells

  • Melones-Herrero, Jorge
  • Delgado-Aliseda, Patricia
  • Figueiras, Sofía
  • Velázquez-Gutiérrez, Javier
  • Gómez Quiroga, Adoración
  • Calés, Carmela
  • Sánchez-Pérez, Isabel
Gastric cancer prognosis is still notably poor despite efforts made to improve diagnosis and treatment of the disease. Chemotherapy based on platinum agents is generally used, regardless of the fact that drug toxicity leads to limited clinical efficacy. In order to overcome these problems, our group has been working on the synthesis and study of trans platinum (II) complexes. Here, we explore the potential use of two phosphine-based agents with the general formula trans-[Pt(amine)Cl2(PPh3)], called P1 and P2 (with dimethylamine or isopropylamine, respectively). A cytotoxicity analysis showed that P1 and especially P2 decrease cell viability. Specifically, P2 exhibits higher activity than cisplatin in gastric cancer cells while its toxicity in healthy cells is slightly lower. Both complexes generate Reactive Oxygen Species, produce DNA damage and mitochondrial membrane depolarization, and finally lead to induced apoptosis. Thus, an intrinsic apoptotic pathway emerges as the main type of cell death through the activation of BAX/BAK and BIM and the degradation of MCL1. Additionally, we demonstrate here that P2 produces endoplasmic reticulum stress and activates the Unfolded Protein Response, which also relates to the impairment observed in autophagy markers such as p62 and LC3. Although further studies in other biological models are needed, these results report the biomolecular mechanism of action of these Pt(II)-phosphine prototypes, thus highlighting their potential as novel and effective therapies., This research was funded by PID2019-106220RB100 granted by MICIU/AEI/10.13039/501100011033 and PID2022-137373OB-I00 granted by MICIU/AEI/10.13039/501100011033/FEDER, UE. J.M.-H. was supported by the grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD programme). P.D.-A. was supported by the Comunidad de Madrid grant PEJ-2023-AI/SAL-GL-28061. S.F. was supported by the Comunidad de Madrid grant PEJ-2021-TL/BMD-22441. J.V.-G. was supported by Programa Investigo, in the frame of Recovery Plan, transformation and Resilience–NextGeneration EU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A select thiosemicarbazone copper(II) complex induces apoptosis in gastric cancer and targets cancer stem cells reducing pluripotency markers

  • Fabra, David
  • Melones-Herrero, Jorge
  • Velázquez-Gutiérrez, Javier
  • Matesanz, Ana I.
  • Aliseda, Patricia D.
  • Figueiras, Sofía
  • Aguilar-Rico, Francisco
  • Calés, Carmela
  • Sánchez-Pérez, Isabel
  • Quiroga, Adoración G.
Copper(II)-based complexes are promising candidates as anti-cancer agents due to their ability to target cancer cells. Here we describe the synthesis and characterization of two copper(II) thiosemicarbazone complexes with the ligands 4-(dimethylamino)benzaldehyde N4-methylthiosemicarbazone (HL1) and 4-(dimethylamino)benzaldehyde N4-(4-(dimethylamino)phenylthiosemicarbazone (HL2) and general formula [Cu(L)2]. The complexes show stability in aqueous solution with 1 % of DMSO that allows to stablish its solution profile in biological buffers. Compound [Cu(L1)₂] lipophilicity was lower than [Cu(L2)₂], however, its solubility in biological buffer was not only better but also its DLS and ζ-potential data. In vitro studies demonstrate a higher cytotoxic effect of [Cu(L1)₂] on gastric cancer cells. The proposed mechanism of action consists in the generation of free radicals that induce DNA lesions, oxidative stress and ultimately autophagy deregulation and apoptosis. Additionally, [Cu(L1)₂] is equally active on gastric cancer stem cells and tumor cells resistant to cisplatin. More importantly, stem cells treated with [Cu(L1)₂] show a downregulation of pluripotency markers such as TWIST, NANOG and OCT4. Overall, our results with [Cu(L1)₂] prompt a significant advancement in the development of rational-designed pharmaceuticals for combating cancer., This research was funded by PID2019-106220RB100 granted by MICIU/AEI/10.13039/501100011033, and PID2022-137373OB-I00 granted by MICIU/AEI/10.13039/501100011033/FEDER, UE. JVG was supported by Programa Investigo, in the frame of Recovery Plan, transformation and Resilience– NextGeneration EU. JMH was supported by a grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD programme). PDA was supported by Comunidad de Madrid grant PEJ-2023-AI/SAL-GL-28061. SFV was supported by Comunidad de Madrid grants PEJ-2021-TL/BMD-22441. FAR was supported by Comunidad de Madrid grants PIPF-2022/SAL-GL-25290, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiproliferative activity in breast cancer cells of PtL2: A steroid-thiosemicarbazone platinum(II) complex

  • Melones-Herrero, Jorge
  • Aguilar-Rico, Francisco
  • Matesanz, Ana I.
  • Calés, Carmela
  • Sánchez-Pérez, Isabel
  • Quiroga, Adoración G.
Breast cancer remains one of the most diagnosed cancers in women worldwide. Metallodrugs such as cisplatin are used in advanced stages and hormone independent tumors. We hereby report the synthesis and characterization of a new benzaldehyde thiosemicarbazone functionalized with an estradiol derivative, LH, and two metal complexes, PdCl2(LH) and PtL2. Both complexes were studied in solution showing enough stability to further perform antitumoral activity studies. The Pd(II) complex was discarded for its poor performance while PtL₂ exhibited similar cytotoxic activity to cisplatin (CDDP) in estrogen receptor (+) and triple-negative breast cancer cells. Moreover, PtL₂ demonstrated reduced toxicity in healthy cell lines. It induced cell cycle arrest at the G0/G1 phase, distinguishing its mechanism of action from CDDP, which predominantly blocks cells in the S phase. Additionally, PtL₂ displayed a balanced intracellular distribution between the nucleus and cytoplasm, independent of estrogen receptor status. Further analysis revealed that PtL₂ dysregulated antioxidant enzyme expression, potentially disrupting redox homeostasis. These findings highlight PtL₂’s potential as a promising alternative to conventional platinum-based therapies, warranting further investigation into its molecular mechanisms and therapeutic applications., This research was funded by PID2019-106220RB100 granted by MICIU/ AEI / 10.13039/501100011033, and PID2022-137373OB-I00 granted by MICIU/ AEI / 10.13039/501100011033 / FEDER, UE. JMH was supported by a grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD programme). FAR was supported by Comunidad de Madrid grants PIPF-2022/SAL-GL-25290., Peer reviewed